Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study

English version České info

Background:
Expanded access to antiretroviral therapy (ART) using universal test and treat (UTT) has been suggested as a strategy to eliminate HIV in South Africa within 7 y based on an influential mathematical modeling study. However, the underlying deterministic model was criticized widely, and other modeling studies did not always confirm the study's finding. The objective of our study is to better understand the implications of different model structures and assumptions, so as to arrive at the best possible predictions of the long-term impact of UTT and the possibility of elimination of HIV.

Methods and Findings:
We developed nine structurally different mathematical models of the South African HIV epidemic in a stepwise approach of increasing complexity and realism. The simplest model resembles the initial deterministic model, while the most comprehensive model is the stochastic microsimulation model STDSIM, which includes sexual networks and HIV stages with different degrees of infectiousness. We defined UTT as annual screening and immediate ART for all HIV-infected adults, starting at 13% in January 2012 and scaled up to 90% coverage by January 2019. All models predict elimination, yet those that capture more processes underlying the HIV transmission dynamics predict elimination at a later point in time, after 20 to 25 y. Importantly, the most comprehensive model predicts that the current strategy of ART at CD4 count ≤350 cells/µl will also lead to elimination, albeit 10 y later compared to UTT. Still, UTT remains cost-effective, as many additional life-years would be saved. The study's major limitations are that elimination was defined as incidence below 1/1,000 person-years rather than 0% prevalence, and drug resistance was not modeled.

Conclusions:
Our results confirm previous predictions that the HIV epidemic in South Africa can be eliminated through universal testing and immediate treatment at 90% coverage. However, more realistic models show that elimination is likely to occur at a much later point in time than the initial model suggested. Also, UTT is a cost-effective intervention, but less cost-effective than previously predicted because the current South African ART treatment policy alone could already drive HIV into elimination.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Med 10(10): e32767. doi:10.1371/journal.pmed.1001534
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001534

Souhrn

Zdroje

1. Joint United Nations Programme on HIV/AIDS (2012) Report on the global AIDS epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS.

2. JohnsonLF, HallettTB, RehleTM, DorringtonRE (2012) The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface 9: 1544–1554.

3. RehleTM, HallettTB, ShisanaO, Pillay-van WykV, ZumaK, et al. (2010) A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS ONE 5: e11094 doi:10.1371/journal.pone.0011094

4. CohenMS, ChenYQ, McCauleyM, GambleT, HosseinipourMC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505.

5. TanserF, BärnighausenT, GrapsaE, ZaidiJ, NewellML (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966–971.

6. DabisF, NewellML, HirschelB (2010) HIV drugs for treatment, and for prevention. Lancet 375: 2056–2057.

7. BaggaleyRF, FergusonNM, GarnettGP (2005) The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2: 9.

8. BaggaleyRF, GarnettGP, FergusonNM (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3: e124 doi:10.1371/journal.pmed.0030124

9. GranichRM, GilksCF, DyeC, De CockKM, WilliamsBG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48–57.

10. MontanerJS, HoggR, WoodE, KerrT, TyndallM, et al. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368: 531–536.

11. SalomonJA, HoganDR, StoverJ, StaneckiKA, WalkerN, et al. (2005) Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2: e16 doi:10.1371/journal.pmed.0020016

12. StoverJ, WalkerN, GarnettGP, SalomonJA, StaneckiKA, et al. (2002) Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 360: 73–77.

13. Velasco-HernandezJX, GershengornHB, BlowerSM (2002) Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2: 487–493.

14. BendavidE, BrandeauML, WoodR, OwensDK (2010) Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 170: 1347–1354.

15. DoddPJ, GarnettGP, HallettTB (2010) Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS 24: 729–735.

16. KretzschmarME, van der LoeffMF, CoutinhoRA (2012) Elimination of HIV by test and treat: a phantom of wishful thinking? AIDS 26: 247–248.

17. PowersKA, GhaniAC, MillerWC, HoffmanIF, PettiforAE, et al. (2011) The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378: 256–268.

18. WagnerBG, KahnJS, BlowerS (2010) Should we try to eliminate HIV epidemics by using a ‘test and treat’ strategy? AIDS 24: 775–776.

19. WalenskyRP, PaltielAD, LosinaE, MorrisBL, ScottCA, et al. (2010) Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 51: 392–400.

20. EatonJW, JohnsonLF, SalomonJA, BärnighausenT, BendavidE, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245 doi:10.1371/journal.pmed.1001245

21. AnglemyerA, RutherfordGW, BaggaleyRC, EggerM, SiegfriedN (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011: CD009153.

22. AttiaS, EggerM, MullerM, ZwahlenM, LowN (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397–1404.

23. DonnellD, BaetenJM, KiarieJ, ThomasKK, StevensW, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092–2098.

24. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infected in adults and adolescents. Geneva: World Health Organization.

25. HontelezJA, de VlasSJ, TanserF, BakkerR, BärnighausenT, et al. (2011) The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE 6: e21919 doi:10.1371/journal.pone.0021919

26. MontanerJS, LimaVD, BarriosR, YipB, WoodE, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532–539.

27. van der PloegCPB, Van VlietC, De VlasSJ, Ndinya-AcholaJO, FransenL, et al. (1998) STDSIM: a microsimulation model for decision support in STD control. Interfaces 28: 84–100.

28. KorenrompEL, BakkerR, De VlasSJ, RobinsonNJ, HayesR, et al. (2002) Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study. Sex Transm Dis 29: 228–238.

29. KorenrompEL, BakkerR, GrayR, WawerMJ, SerwaddaD, et al. (2002) The effect of HIV, behavioural change, and STD syndromic management on STD epidemiology in sub-Saharan Africa: simulations of Uganda. Sex Transm Infect 78 (Suppl 1) i55–i63.

30. KorenrompEL, Van VlietC, BakkerR, De VlasSJ, HabbemaJD (2000) HIV spread and partnership reduction for different patterns of sexual behavior—a study with the microsimulation model STDSIM. Math Pop Studies 8: 135–173.

31. van VlietC, MeesterEI, KorenrompEL, SingerB, BakkerR, et al. (2001) Focusing strategies of condom use against HIV in different behavioural settings: an evaluation based on a simulation model. Bull World Health Organ 79: 442–454.

32. KorenrompEL, Van VlietC, GrosskurthH, GavyoleA, Van der PloegCP, et al. (2000) Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 14: 573–593.

33. WhiteRG, FreemanEE, OrrothKK, BakkerR, WeissHA, et al. (2008) Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect 84 (Suppl 2) ii12–ii18.

34. WhiteRG, GlynnJR, OrrothKK, FreemanEE, BakkerR, et al. (2008) Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 22: 1841–1850.

35. OrrothKK, FreemanEE, BakkerR, BuveA, GlynnJR, et al. (2007) Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 83 (Suppl 1) i5–i16.

36. HontelezJA, LurieMN, NewellML, BakkerR, TanserF, et al. (2011) Ageing with HIV in South Africa. AIDS 25: 1665–1667.

37. HontelezJA, NagelkerkeN, BärnighausenT, BakkerR, TanserF, et al. (2011) The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model. Vaccine 29: 6100–6106.

38. HontelezJAC, De VlasSJ, BaltussenR, NewellM, BakkerR, et al. (2012) The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS 26 (Suppl 1) S19–S30.

39. United Nations Population Division Fertility and Family Planning Section (2008) World fertility data 2008 [database]. New York: United Nations Population Division Fertility and Family Planning Section.

40. World Health Organization (2011) Life tables for WHO member States. Geneva: World Health Organization.

41. World Health Organization (2008) The global burden of disease: 2004 update. Geneva: World Health Organization.

42. JaffarS, GrantAD, WhitworthJ, SmithPG, WhittleH (2004) The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ 82: 462–469.

43. MorganD, MaheC, MayanjaB, OkongoJM, LubegaR, et al. (2002) HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16: 597–603.

44. BoilyMC, BaggaleyRF, WangL, MasseB, WhiteRG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118–129.

45. HollingsworthTD, AndersonRM, FraserC (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687–693.

46. South Africa Department of Health (2003) Demographic and Health Survey of South Africa. Pretoria: South Africa Department of Health.

47. WilliamsBG, Lloyd-SmithJO, GouwsE, HankinsC, GetzWM, et al. (2006) The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med 3: e262 doi:10.1371/journal.pmed.0030262

48. AuvertB, TaljaardD, LagardeE, Sobngwi-TambekouJ, SittaR, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298 doi:10.1371/journal.pmed.0020298

49. BaileyRC, MosesS, ParkerCB, AgotK, MacleanI, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643–656.

50. GrayRH, KigoziG, SerwaddaD, MakumbiF, WatyaS, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657–666.

51. MutevedziPC, LessellsRJ, RodgerAJ, NewellML (2011) Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS ONE 6: e21795 doi:10.1371/journal.pone.0021795

52. WilliamsBG, KorenrompEL, GouwsE, SchmidGP, AuvertB, et al. (2006) HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis 194: 1450–1458.

53. World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization.

54. HargreavesJR, BonellCP, MorisonLA, KimJC, PhetlaG, et al. (2007) Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001–2004. AIDS 21 (Suppl 7) S39–S48.

55. BadriM, MaartensG, MandaliaS, BekkerLG, PenrodJR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3: e4 doi:10.1371/journal.pmed.0030004

56. HarlingG, WoodR (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 348–354.

57. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.

58. CohenMS, ShawGM, McMichaelAJ, HaynesBF (2011) Acute HIV-1 infection. N Engl J Med 364: 1943–1954.

59. TanserF, HosegoodV, BärnighausenT, HerbstK, NyirendaM, et al. (2008) Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 37: 956–962.

60. HerbstAJ, CookeGS, BärnighausenT, KanyKanyA, TanserF, et al. (2009) Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ 87: 754–762.

61. HontelezJA, NewellML, BlandRM, MunnellyK, LessellsRJ, et al. (2012) Human resources needs for universal access to antiretroviral therapy in South Africa: a time and motion study. Hum Resour Health 10: 39.

62. BärnighausenT (2010) The role of the health system in HIV treatment-as-prevention. AIDS 24: 2741–2742.

63. BärnighausenT, TanserF, DabisF, NewellML (2012) Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS 7: 140–150.

64. KranzerK, LewisJJ, FordN, ZeineckerJ, OrrellC, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 55: e17–e23.

65. CornellM, GrimsrudA, FairallL, FoxMP, van CutsemG, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS 24: 2263–2270.

66. Garcia-CallejaJM, GouwsE, GhysPD (2006) National population based HIV prevalence surveys in sub-Saharan Africa: results and implications for HIV and AIDS estimates. Sex Transm Infect 82 (Suppl 3) iii64–iii70.

67. NyirendaM, ZabaB, BärnighausenT, HosegoodV, NewellML (2010) Adjusting HIV prevalence for survey non-response using mortality rates: an application of the method using surveillance data from rural South Africa. PLoS ONE 5: e12370 doi:10.1371/journal.pone.0012370

68. GranichR, KahnJG, BennettR, HolmesCB, GargN, et al. (2012) Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS ONE 7: e30216 doi:10.1371/journal.pone.0030216

69. NagelkerkeNJ, JhaP, de VlasSJ, KorenrompEL, MosesS, et al. (2002) Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 80: 89–96.

70. HamersRL, WallisCL, KityoC, SiwaleM, MandaliyaK, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750–759.

71. ManasaJ, KatzensteinD, CassolS, NewellML, de OliveiraT (2012) Primary drug resistance in South Africa—data from 10 years of surveys. AIDS Res Hum Retroviruses 28: 558–565.

72. NachegaJB, MillsEJ, SchechterM (2010) Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 5: 70–77.

73. MillsEJ, BakandaC, BirungiJ, MwesigwaR, ChanK, et al. (2011) Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 25: 851–855.

74. BorJ, HerbstAJ, NewellML, BärnighausenT (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961–965.

75. BorJ, TanserF, NewellML, BärnighausenT (2012) In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. Health Aff (Millwood) 31: 1459–1469.

76. Abdool KarimSS, ChurchyardGJ, KarimQA, LawnSD (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374: 921–933.

77. United Nations Population Division (2010) World population prospects: the 2010 revision. New York: United Nations Population Division.

78. Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, et al.. (2005) South African national HIV prevalence, behavioural risks and communication survey, 2005. Cape Town: HSRC Press.

79. JohnsonLF, AlkemaL, DorringtonRE (2010) A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 86: 169–174.

80. HoulihanCF, BlandR, MutevedziP, LessellsRJ, NdiranguJ, et al. (2011) Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 40: 318–326.

81. WilliamsBG, GranichR, DyeC (2011) Role of acute infection in HIV transmission. Lancet 378: 1913.

82. BärnighausenT, TanserF, NewellML (2009) Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003–2007. AIDS Res Hum Retroviruses 25: 405–409.

83. KumaranayakeL (2008) The economics of scaling up: cost estimation for HIV/AIDS interventions. AIDS 22 (Suppl 1) S23–S33.

84. JohnsonLF, DorringtonRE, BradshawD, Pallay-Van WykV, RehleT (2009) Sexual behaviour patterns in South Africa and their association with the spread of HIV: insights from a mathematical model. Demogr Res 21: 289–340.

85. CaraelM, ClelandJ, AdeokunL (1991) Overview and selected findings of sexual behaviour surveys. AIDS 5 (Suppl 1) S65–S74.

86. NnkoS, BoermaJT, UrassaM, MwalukoG, ZabaB (2004) Secretive females or swaggering males? An assessment of the quality of sexual partnership reporting in rural Tanzania. Soc Sci Med 59: 299–310.

87. WeinhardtLS, ForsythAD, CareyMP, JaworskiBC, DurantLE (1998) Reliability and validity of self-report measures of HIV-related sexual behavior: progress since 1990 and recommendations for research and practice. Arch Sex Behav 27: 155–180.